神经药理学报

神经药理学报 ›› 2022, Vol. 12 ›› Issue (6): 8-15.DOI: 10.3969/j.issn.2095-1396.2022.06.002

• 研究论文 • 上一篇    下一篇

依达拉奉治疗缺血性脑卒中临床疗效的 Meta 分析

王莉菲，李书瑞   

  1. 1. 河北北方学院研究生学院，张家口，075000，中国  2. 邯郸市中心医院老年病科，邯郸，056000，中国
  • 出版日期:2022-12-26 发布日期:2023-08-30
  • 通讯作者: 李书瑞，主任医师，硕士，硕士生导师；研究方向：老年心脑血管；E-mail：Li.shurui@aliyun.com
  • 作者简介:王莉菲，医师，硕士研究生；E-mail：wanglifei30@163.com

Meta-Analysis of the Clinical Efficacy of Edaravone in the Treatment of Ischaemic Stroke

WANG Li-fei，LI Shu-rui   

  1. 1. Graduate School of Hebei North University，Zhangjiakou，075000，China  2. Department of Geriatrics，Handan Central Hospital，Handan，056000，China
  • Online:2022-12-26 Published:2023-08-30

PDF (PC)

22

摘要：

目的：系统性地评估依达拉奉对缺血性脑卒中疗效。方法：在中国知网、万方和维普期刊、Cochrane、 Embase、Pubmed、ClinicalTrials 中应用计算机检索，设定年限为各数据库建库至2022 年12 月，选择有关应 用依达拉奉治疗缺血性脑卒中的相关随机对照及临床试验的文献，采用Cochrane 风险评估表，对所检索文献 质量评估，利用Revman 5.4 软件包提取有关试验资料，对结果进行Meta 分析。结果：共纳入28 项临床试验， Meta 分析显示，应用依达拉奉治疗缺血性脑卒中后美国国立卫生研究院卒中量表（national institute of health stroke，NIHSS）评分［MD=-3.85，95%CI（-4.94，-2.77）］，日常生活活动能力（activities of daily living，ADL）评分 ［MD=13.37，95%CI（11.05，15.69）］，各项指标治愈程度均好于常规治疗。结论：依达拉奉治疗缺血性脑卒中的临 床疗效优于常规治疗方法，但仍需高质量的临床研究进一步佐证。

关键词: 依达拉奉, 临床疗效, 缺血性脑卒中, Meta 分析

Abstract:

Objective：To systematically evaluate the therapeutic effect of Edaravone on ischemic stroke. Methods：A computer search was conducted in Cochrane Library，Pubmed， Embase，ClinicalTrials，China knowledge Network database，Wanfang database and VIP periodical resource database. The years were set for each database to be built until December 2022. The literatures about randomized controlled trials and clinical trials of Edaravone in the treatment of ischemic stroke were selected，and the Cochrane risk assessment form was used to evaluate the quality of the retrieved literature. The experimental data related to research were extracted by Revman5.4 software and analyzed by Meta. Results：A total of 28 clinical trials were included. Meta-analysis showed that NIHSS score ［MD=-3.85，95% CI（-4.94，-2.77）］ and ADL score ［MD=13.37，95%CI（11.05，15.69）］ in the treatment of ischemic stroke with Edaravone. The improvement of related indexes was better than that of conventional treatment. Conclusion： The clinical efficacy of Edaravone in the treatment of ischemic stroke is better than that of conventional treatment，but high-quality clinical studies are still needed for further evidence.

Key words: edaravone, clinical efficacy, ischemic stroke, meta analysis